SCHEMBL3264562

SCHEMBL3264562

CC(C)(C)OC(=O)N1CCCN(c2nc3ccccc3o2)CC1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.59
KMT2A Q03164 1/20 0.59
LMNA P02545 5/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
HTT P42858 3/20 0.59
TSHR P16473 2/20 0.53
CKS1B P61024 2/20 0.53
SKP1 P63208 2/20 0.53
SKP2 Q13309 2/20 0.53
NAAA Q02083 1/20 0.53
CNR2 P34972 4/20 0.52
HCAR2 Q8TDS4 1/20 0.50
PDE10A Q9Y233 1/20 0.49
MAPT P10636 1/20 0.49
PIK3CA P42336 1/20 0.46
GBA1 P04062 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058660 0.95 GAA (0.64) GAAKMT2ALMNASMN1; SMN2HTT
SCHEMBL13094458 0.87 CNR2 (0.50) GAAKMT2ALMNASMN1; SMN2HTT
SCHEMBL13094453 0.87 CKS1B (0.55) GAAKMT2ALMNASMN1; SMN2HTT
SCHEMBL3075253 0.85 PTGES (0.62) KMT2ACNR2PIK3CA
SCHEMBL3078363 0.85 PTGES (0.52) KMT2ALMNASMN1; SMN2HTTCKS1B
SCHEMBL6110987 0.81 ELANE (0.60) GAAKMT2ALMNASMN1; SMN2HTT
SCHEMBL13279367 0.81 PIK3CA (0.52) GAAKMT2ALMNASMN1; SMN2HTT
SCHEMBL389868 0.81 GAA (0.64) GAAKMT2ALMNASMN1; SMN2HTT
SCHEMBL3074712 0.81 CKS1B (0.47) KMT2ALMNASMN1; SMN2TSHRCKS1B
SCHEMBL13894571 0.80 CNR2 (0.49) GAAKMT2ALMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144712-A1 TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-06-10 US disclosed
EP-2167490-A1 TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Korea Research Institute Of Chemical Technology (KR) 2010-03-31 EP disclosed
WO-2008153325-A1 TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144712-A1 TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CYP51A1, ERG28, CYP3A7 GAA 288/4885KMT2A 2959/4885LMNA 3738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.